N/A N=33 Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
Phase 3 N=308 Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants
Hepatitis B
Primary: Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies — 100; 100; 100; 100 IU/mL
Phase 3 N=698 Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
Meningococcal Infection
Primary: Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at…
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
N/A N=105 Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Efficacy of the New CPRV
Primary: Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT) — 0; 0; 0 International unit per ml
Phase 4 N=54 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
Herpes Zoster
Primary: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV — 45; 9 Participants
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
Phase 2 N=34 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Cholera
Primary: Level of Antibody Titers in Serum — 76; 2671 Vibriocidal antibody titer
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
N/A N=174 Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Vaccine Response Impaired
Primary: Antibody Titer Responses to Hepatitis B Virus Surface Antigen (HBV sAg) Vaccine, Measured and Predicted Based on Pre-vaccination Biomarkers in Healthy, Elderly…
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Phase 4 N=136 Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 4 N=49 Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.
Hepatitis B
Primary: Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). — 8; 13…
Phase 3 N=1,315 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Bacterial Infections · Virus Diseases
Primary: Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)…
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
Phase 2 N=216 B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Meningococcal Disease
Primary: Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y — 2.10; 1.80; 1.72; 2.57 B cells per 2x100000 lymphocytes — p=0.69
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 4 N=10 Immune Response to Shingles Vaccination
Shingles
Primary: Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood — 0.02 percentage of CD4 T cells
Phase 4 N=86 Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 42; 19; 25 Participants
N/A N=88 Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
Phase 2 N=34 Effects of Age on Response to the 2009 H1N1 Virus Vaccine
2009 H1N1 Influenza Virus
Primary: Number of Participants Who Shed Virus — 0 participants
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Phase 3 N=267 Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity
Influenza
Primary: Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1) — 41; 34 participants
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 4 N=18 Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
Human Papillomavirus
Primary: B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) — 0.61; 0.94; 0.36; 0.08 % of memory B cells that are Ag-specific
N/A N=66 Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants